Clinical & Experimental Cardiology
Open Access
ISSN: 2155-9880
+44 1300 500008
ISSN: 2155-9880
+44 1300 500008
Lale Hakami, Christian Hagl, Nikolaus Haas, Robert Dalla Pozza, Sarah Ulrich, Anja Lehner and Linda Haase
University of Munich, Germany
Scientific Tracks Abstracts: J Clin Exp Cardiolog
Introduction & Aim: Heart transplantation is the last surgical option for infants and young children with congenital heart failure after failed conventional repair or palliative procedures. We aim to present our results in a retrospective and descriptive analysis. Methods: 18 heart transplantations on children (nine female, nine male) were performed from 1988 to 2015. The range of age was between 0 days and 3 years. Indications for a transplantation were hypoplastic left heart syndrome (n=14), noncompaction-syndrome (n=2), bland-white-garland-syndrome (n=1) and transposition of the great arteries (n=1). 14 children (78%) had had a previous cardiac surgery. Four patients (22%) required mechanical circulatory support for bridging: ECMO (n=2; 11%), or LVAD and ECMO (n=2; 11%). 15 (83%) underwent a biatrial method, three (17%) a bicaval one. Results: The median waiting time after listing was 68 days (min: 0 days, max: 386 days, standard deviation (SD): 102.8 days). The overall survival was 61%, 13 children (72%) survived the first year. Two patients (11%) had a re-transplantation. The median time patients spent at intensive care unit was 17 days (min: 1 day; max: 121 days). They were respirated for 7 days (min: 1 day; max: 91 days). Perioperative factors we analyzed were the median myocardial ischemia time was 236 minutes, the median aortic clamp time was 95 minutes and the median time of circulatory arrest was 60 minutes. Three children (17%) got a pericardial effusion. Two patients (11%) suffered each: Bleeding, cardiac arrhythmias, diaphragmatic paresis and cerebral complications. Five (28%) got a lymphoproliferative disease. Seven children (39%) got a coronary graft vasculopathy. Two (11%) needed interventional therapy. Three (17%) got a cardiac pace maker. According to our data, six children had a rejection which called for treatment. Conclusion: Heart transplantation is still the best therapeutic option after end-stage heart failure in children. Cumulative results suggest one additional year of life in more than 70% and a survival of more than 20 years is possible. These results were comparable to those of the ISHLT registry in pediatrics.
Lale Hakami has her expertise in pediatric cardiac surgery in infants and newborn. She is a German board certified Cardiac Surgeon with a subspecialization in Pediatric Cardiac Surgery. She was the Junior Consultant of the Congenital Heart Surgery at the University Hospital Erlangen, Germany (2006-2008), Research Fellowship at the Children's Hospital Boston, USA (2008-2009) and was the Director of Pediatric Cardiac Surgery in Mainz, Germany (2009-2011). She has also worked as Senior Consultant in Children Heart Center in Linz, Austria and since 2014 she is Senior Consultant at the University Hospital Munich, Germany and University Lecture of Pediatric Cardiac Surgery at Ludwig-Maximilians-University Munich, Germany (LMU). Her particular experience is in single ventricle physiology and heart transplantation in infants and newborn.
Email:Lale.Hakami@med.uni-muenchen.de